Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature
Abstract Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63‐year‐old woman with stage IVA lung adenocarcinoma given pembrolizumab as a fi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13399 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221991717928960 |
|---|---|
| author | Kazuaki Harada Makoto Ogasawara Akane Shido Akimitsu Meno Soichiro Oda Shota Yoshida Sonoe Yoshida Ayumu Yoshikawa Ko Ebata Satoshi Abiko Naoki Kawagishi Itsuki Sano Hisashi Oda Takuto Miyagishima |
| author_facet | Kazuaki Harada Makoto Ogasawara Akane Shido Akimitsu Meno Soichiro Oda Shota Yoshida Sonoe Yoshida Ayumu Yoshikawa Ko Ebata Satoshi Abiko Naoki Kawagishi Itsuki Sano Hisashi Oda Takuto Miyagishima |
| author_sort | Kazuaki Harada |
| collection | DOAJ |
| description | Abstract Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63‐year‐old woman with stage IVA lung adenocarcinoma given pembrolizumab as a first‐line therapy. After four cycles of pembrolizumab treatment, the patient suddenly developed a pericardial tamponade. Although pericardial effusion was increased, her tumor lesions were reduced. After an emergency pericardiocentesis, she continued the pembrolizumab therapy without recurrent pericardial effusions for three months until the primary tumor and lymph node metastasis progressed. Nine months after the pericardiocentesis, the patient died of progressive lung cancer, but pericardial effusion did not recur throughout the treatment course. This case study suggests that pembrolizumab therapy can be continued with a strict follow‐up in some patients with pembrolizumab‐induced pericardial tamponade. Key points • Significant findings of the study Our patient developed pericardial tamponade during pembrolizumab treatment but continued pembrolizumab treatment after emergency pericardiocentesis without recurrent pericardial effusions. • What this study adds Pembrolizumab treatments may be resumed with a strict follow‐up in some patients with treatment‐related pericardial tamponade. |
| format | Article |
| id | doaj-art-71c79c31b16a44a5aa306e598f2a22b5 |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2020-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-71c79c31b16a44a5aa306e598f2a22b52025-08-26T10:24:35ZengWileyThoracic Cancer1759-77061759-77142020-05-011151350135310.1111/1759-7714.13399Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literatureKazuaki Harada0Makoto Ogasawara1Akane Shido2Akimitsu Meno3Soichiro Oda4Shota Yoshida5Sonoe Yoshida6Ayumu Yoshikawa7Ko Ebata8Satoshi Abiko9Naoki Kawagishi10Itsuki Sano11Hisashi Oda12Takuto Miyagishima13Department of Medical Oncology Kushiro Rosai Hospital Kushiro JapanDepartment of Cardiovascular Medicine Kushiro Kojinkai Kinen Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanDepartment of Internal Medicine Kushiro Rosai Hospital Kushiro JapanAbstract Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63‐year‐old woman with stage IVA lung adenocarcinoma given pembrolizumab as a first‐line therapy. After four cycles of pembrolizumab treatment, the patient suddenly developed a pericardial tamponade. Although pericardial effusion was increased, her tumor lesions were reduced. After an emergency pericardiocentesis, she continued the pembrolizumab therapy without recurrent pericardial effusions for three months until the primary tumor and lymph node metastasis progressed. Nine months after the pericardiocentesis, the patient died of progressive lung cancer, but pericardial effusion did not recur throughout the treatment course. This case study suggests that pembrolizumab therapy can be continued with a strict follow‐up in some patients with pembrolizumab‐induced pericardial tamponade. Key points • Significant findings of the study Our patient developed pericardial tamponade during pembrolizumab treatment but continued pembrolizumab treatment after emergency pericardiocentesis without recurrent pericardial effusions. • What this study adds Pembrolizumab treatments may be resumed with a strict follow‐up in some patients with treatment‐related pericardial tamponade.https://doi.org/10.1111/1759-7714.13399Immune checkpoint inhibitorpembrolizumabpericardial effusionpericardial tamponade |
| spellingShingle | Kazuaki Harada Makoto Ogasawara Akane Shido Akimitsu Meno Soichiro Oda Shota Yoshida Sonoe Yoshida Ayumu Yoshikawa Ko Ebata Satoshi Abiko Naoki Kawagishi Itsuki Sano Hisashi Oda Takuto Miyagishima Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature Thoracic Cancer Immune checkpoint inhibitor pembrolizumab pericardial effusion pericardial tamponade |
| title | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
| title_full | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
| title_fullStr | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
| title_full_unstemmed | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
| title_short | Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature |
| title_sort | pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma a case report and review of the literature |
| topic | Immune checkpoint inhibitor pembrolizumab pericardial effusion pericardial tamponade |
| url | https://doi.org/10.1111/1759-7714.13399 |
| work_keys_str_mv | AT kazuakiharada pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT makotoogasawara pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT akaneshido pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT akimitsumeno pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT soichirooda pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT shotayoshida pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT sonoeyoshida pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT ayumuyoshikawa pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT koebata pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT satoshiabiko pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT naokikawagishi pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT itsukisano pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT hisashioda pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature AT takutomiyagishima pericardialtamponadeduringpembrolizumabtreatmentinapatientwithadvancedlungadenocarcinomaacasereportandreviewoftheliterature |